SEAL ROCK THERAPEUTICS
Seal Rock Therapeutics is a developer of small-molecule inhibitors of ASK1 (Apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and fibrosis. Seal Rock is currently focusing its efforts on hepatic indications including NASH (non-alcoholic steatohepatitis), a condition resulting from fatty liver disease, characterized by hepatic inflammation and cellular damage that lead to liver fibrosis. Additional opportunities with ASK1 inhibitors include cardiac, immunological, and neurodegenerative indications.
SEAL ROCK THERAPEUTICS
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2016-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.sealrocktx.com
Total Employee:
1+
Status:
Active
Contact:
786.453.0593
Email Addresses:
[email protected]
Total Funding:
0
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Apple Mobile Web Clips Icon Content Delivery Network Euro Microsoft Exchange Online Office 365 Mail
Current Employees Featured
Founder
Investors List
Life Science Angels
Life Science Angels investment in Seed Round - Seal Rock Therapeutics
Life Science Angels
Life Science Angels investment in Seed Round - Seal Rock Therapeutics
Official Site Inspections
http://www.sealrocktx.com
- Host name: performance-center.az
- IP address: 192.185.16.193
- Location: Houston United States
- Latitude: 29.8284
- Longitude: -95.4696
- Metro Code: 618
- Timezone: America/Chicago
- Postal: 77092
More informations about "Seal Rock Therapeutics"
About Us - sealrocktx.com
A highly experienced team that has been involved in the discovery, development, and commercialization of over 20 FDA approved drugs.See details»
Seal Rock Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 786.453.0593 Seal Rock Therapeutics is a developer of small-molecule inhibitors of ASK1 (Apoptosis signal-regulating kinase 1), a …See details»
Seal Rock Therapeutics - PitchBook
Jan 2, 2018 Information on valuation, funding, cap tables, investors, and executives for Seal Rock Therapeutics. Use the PitchBook Platform to explore the full profile.See details»
Contact | Seal Rock Therapeutics
[email protected] We welcome collaborations with organizations addressing the challenges of developing therapies for liver and neurodegenerative diseases. Contact us to explore …See details»
Seal Rock Therapeutics Overview | SignalHire Company Profile
Phone Number: 786.453.0593: Seal Rock Therapeutics industries Biotech: Headquarters Location: 500 Yale Ave N, Seattle, WA, 98109 US 500 Yale Ave N, Seattle, WA... Seal Rock …See details»
Seal Rock Therapeutics: Contact Details and Business Profile
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and …See details»
Seal Rock Therapeutics - Overview, News & Similar companies
Seal Rock Therapeutics contact info: Phone number: (206) 401-5086 Website: www.sealrocktx.com What does Seal Rock Therapeutics do? Led by an experienced …See details»
Seal Rock Therapeutics - Company Profile - Tracxn
Dec 5, 2024 Seal Rock Therapeutics - Provider of therapeutics for liver fibrosis. Raised funding over 1 round from 4 investors. Founded by Neil McDonnell, Artur Plonowski and 1 other in the …See details»
Seal Rock Therapeutics, Inc.
Abstract selected as TOP abstract for Congress Presentation SEATTLE, May 29, 2024 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in …See details»
Seal Rock Therapeutics | LinkedIn
Seal Rock Therapeutics, Inc. is discovering and developing small molecule inhibitors of ASK1 (apoptosis signal-regulating kinase 1), a protein that mediates apoptosis, inflammation, and …See details»
Seal Rock Therapeutics Company Overview, Contact Details
ASIK1 Inhibitors Seal Rock Therapeutics specializes in small molecule ASK1 inhibitors, offering potential solutions for hepatic indications like NASH, presenting a promising opportunity for …See details»
Seal Rock Therapeutics to Present at Biotech Showcase 2023 - PR …
Jan 5, 2023 For more information, please visit www.sealrocktx.com. Media Contact: Julie Rathbun Rathbun Communications [email protected] 206-769-9219. SOURCE Seal Rock …See details»
Seal Rock Therapeutics Announces Out-Licensing Agreement with …
May 31, 2023 For more information, please visit www.sealrocktx.com. Media Contact: Julie Rathbun Rathbun Communications [email protected] 206-769-9219. SOURCE Seal Rock …See details»
Our Science - sealrocktx.com
SRT-015 has shown an excellent efficacy in multiple preclinical models of acute and chronic liver injury. SRT-015 has completed phase 1 clinical trial (NCT04887038) in healthy volunteers, …See details»
sealrocktx.com Reviews | check if site is scam or legit| Scamadviser
Why does sealrocktx.com have an average to good trust score?. sealrocktx.com is very likely not a scam but legit and reliable. Our algorithm gave the review of sealrocktx.com a relatively high …See details»
www.sealrocktx.org
Www.sealrocktx.orgSee details»
Our Pipeline - sealrocktx.com
Kinases are important drug targets that play a prominent role in the pathogenesis of many life-threatening and debilitating diseases. Our focus is on the development and commercialization …See details»
A Shrimper’s Crusade Pays Big Dividends on a Remote Stretch of …
4 days ago To help the fishermen build a sustainable business, Wilson tapped the Federation of Southern Cooperatives, an organization based in Atlanta originally founded to help Black …See details»
nov-16-2020 - sealrocktx.com
November 16, 2020, Seattle, WA – Seal Rock Therapeutics, Inc., a late-preclinical stage biotechnology company developing first-in-class and best-in-class treatments for severe liver …See details»
jan-5-2023 - sealrocktx.com
January 5, 2023, Seattle, WA – Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced that Neil …See details»